Did Takeda Make The Right Decisions Throughout The Uloric Review?
This article was originally published in Pharmaceutical Approvals Monthly
When FDA first turned Uloric down for approval, the agency stipulated that the cardiovascular adverse event issue needed further evaluation "by providing further comparative controlled clinical safety data, or, possibly, through reanalyses of the current database." The agency's letter adds, "Should a differential signal of thromboembolic CV events remain upon the analysis of new data and/or reanalyses of existing data, we would strongly encourage you to consider proposing the use of lower doses of Uloric, rather than those proposed."
You may also be interested in...
Within the review teams at FDA, there is the sentiment that the broadened safety authorities granted under the FDA Amendments Act allow the agency to approve drugs that it previously would have considered unapprovable, as an office director in the Center for Drug Evaluation and Research makes clear in the review documents for Takeda’s gout therapy Uloric (febuxostat).
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class